Evaluation of the Effectiveness of Some Proton Pump Inhibitors, Cytoprotectors and their Combinations on Nitric Oxide Synthesis in Gastric Mucosa in Indomethacin Gastropathy
##plugins.themes.bootstrap3.article.main##
摘要
Purpose: To evaluate the effectiveness of the action of certain proton pump inhibitors, cytoprotectors, and their combinations on the performance of the synthesis of nitric oxide in the gastric mucosa in indomethacin gastropathy.
Material and methods: Biochemical studies were conducted on 14 groups of animals: Group 1 - intact; Group 2 - animals with indomethacin gastropathy (IG); Group 3 - animals with IG treated with distilled water for 10 days (without treatment); Group 4 - animals with IG treated with omeprazole for 10 days; Group 5 - animals with IG treated with rabeprazole for 10 days; Group 6 - animals with IG + de-nol - 10 days; Group 7 - animals with IG + sucralfat 10 days; Group 8 - animals with IG + pepsan-R - 10 days; Group 9 - animals with IG + omeprazole + de-nol - 10 days; Group 10 - animals with IG + omeprazole + sucralfate - 10 days; Group 11 - animals with IG + omeprazole + pepsan-P - 10 days; Group 12 - animals with IG + rabeprazole + De-Nol - 10 days; Group 13 - animals with IG + rabeprazole + sucralfate - 10 days; Group 14 - animals with IG + rabeprazole + pepsan-P - 10 days. For biochemical studies, animals were scored under ether anesthesia by single-step decapitation. Removed the stomach, washed, scraped mucous and slurried.
Results: We found that de-nol and pepsan-P stimulate NO-formation, but sucralfate does not affect. Our results suggest that the effectiveness of De-Nol and pepsan-P is due to their inductive effect on the activity of the key enzyme NO-formation - NADPH diaphorase.
Conclusions: 1. Sucralfate does not affect these mechanisms. Rabeprazole, De-Nol and pepsan-P to a single degree stimulate NO in the mucous tissue of the stomach during IG. 2. For the stimulation of NO-formation in the mucous tissue of the stomach is more effective is the combined use of rabeprazole with pepsan-P and rabeprazole with De-Nol and less effective omeprazole with pepsan-R.
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##
##submission.citations##
Use of antioxidant plant preparations in radiation damage of lung surfactant /M. B. Palagina, M. A. Haisna, G. N. Bezdetko et al. // 6th National Congress on Respiratory Diseases. - Novosibirsk, 1996. - № 1729.
Kalinin A. V. Complications of the gastrointestinal tract in the use of nonsteroidal anti-inflammatory drugs //Ros. Zhurn. gastroenterolog. gepatol. koloproktol. - 1994. - Vol. 4, No. 1.
Karataev A. E., Nasonova V. A. Evaluation of the effect of glucocorticosteroid and nonsteroidal anti-inflammatory drugs on the development of erosive-ulcerous lesions of the gastrointestinal tract in patients with rheumatic diseases // Ter. archiv. -1999. - № 2. - C. 26-30.
Karimov H. Y., Usmonov I. M., Karimov K. R. Enzymes of the initial and final stages of hydrolysis of carbohydrates in long-term experimental duodenal ulcer // Uzbek Tibbiyot Journal. - 2000. - № 3. - С. 85-87.
Maev I. V., Andreev D.N., Dicheva D.E., Goncharenko A.Yu. Pharmacotherapeutic aspects of the use of proton pump inhibitors // Medical Bulletin of the Ministry of Internal Affairs. 2013. № 3 (64). С. 9-14.
Nasonova V. A. Gastropathies associated with the intake of nonsteroidal anti-inflammatory drugs //Ros. zhurn. gastroenterolog., gepatol., koloproktol. - 1994. - Т.4, № 1. - C. 7-10.
Radbil O. S. Some problems of cytoprotection of the mucous membrane of the stomach and 12-perestine // Clin. med. - 1990. - №4. -С. 31-38.
Ramenskaya G. V., Serebrova S. Yu. V., Serebrova S. Yu. Assessment of relative bioavailability and clinical efficacy of omeprozole // Clin. pharm. and therapy. - 2001. - № 1. - C. 12-14.
Sulaeva ON, Wallace JL Prospects for the development of anti-inflammatory drugs safe for the gastrointestinal tract. // Clin Med.
Gastroduodenal lesion induced by non-steroidal 2017; 95(3):222-7.
Gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Dec; 60(12):1650-9.
Khan S, Mohammad A, O'Rourke KP. An audit of the frequency of proton pump inhibitor (PPI) prescription in rheumatoid arthritis (RA) patients taking non-steroidal anti-inflammatory drugs (NSAIDs). Ir J Med Sci. 2014 Dec; 183(4):685-6.
Koffeman AR, Valkhoff VE, Çelik S, et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. The British Journal of General Practice. 2014; 64(621).
Mo C, Sun G, Lu M-L, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World Journal of Gastroenterology: WJG. 2015; 21(17): 5382-5392.
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP;
COGENT researchers. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71.